Mycoses in Neonates and Children

  • Tanu SinghalEmail author


Children at risk for invasive fungal infections (IFI) include neonates, critically sick children, children on cancer chemotherapy/stem cell transplant and those with primary or acquired immunodeficiency (Table 7.1). Like adults, the incidence of IFI in children is also increasing due to increase in the ‘at-risk group’. But limited trial data and non-availability of many paediatric antifungal formulations complicate treatment of IFI in children even more than adults. The burden and outcome of paediatric IFI in Asian countries are likely to be worse than resource-rich settings due to poor infection control practices in neonatal and paediatric intensive care units, overuse of antibiotics, increased mold spore counts in the hospital environment and residential dwellings, tropical climate, malnutrition, advanced disease at diagnosis, reduced awareness, lack of appropriate diagnostic facilities and cost/availability of antifungal drugs. This write-up gives a bird’s eye view of IFI in children from an Asian perspective. While knowledge and attention to guidelines is essential, what is more important is to formulate diagnostic and treatment algorithms based on local epidemiology, resources and availability.


  1. 1.
    Saiman L, Ludington E, P faller M, et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J. 2000;19:319.CrossRefGoogle Scholar
  2. 2.
    Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birthweight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117:84–92.CrossRefGoogle Scholar
  3. 3.
    Basu S, Kumar R, Tilak R, Kumar A. Candida blood stream infection in neonates: experience from a Tertiary Care Teaching Hospital of Central India. Indian Pediatr. 2017;54(7):556–9.CrossRefGoogle Scholar
  4. 4.
    Jajoo M, Manchanda V, Chaurasia S, Sankar MJ, Gautam H, Agarwal R, et al. Investigators of the Delhi Neonatal Infection Study (DeNIS) Collaboration, New Delhi, India. Alarming rates of antimicrobial resistance and fungal sepsis in outborn neonates in North India. PLoS One. 2018;13(6):e0180705.CrossRefGoogle Scholar
  5. 5.
    Ariff S, Saleem AF, Soofi SB, Sajjad R. Clinical spectrum and outcomes of neonatal candidiasis in a tertiary care hospital in Karachi, Pakistan. J Infect Dev Ctries. 2011;5:216–23.CrossRefGoogle Scholar
  6. 6.
    Chakrabarti A, Singh K, Narang A, Singhi S, Batra R, Rao KL, et al. Outbreak of Pichia anomala infection in the pediatric service of a tertiary-care center in Northern India. J Clin Microbiol. 2001;39:1702–6.CrossRefGoogle Scholar
  7. 7.
    Patra S, Vij M, Chirla DK, Kumar N, Samal SC. Unsuspected invasive neonatal gastrointestinal mucormycosis: a clinicopathological study of six cases from a tertiary care hospital. J Indian Assoc Pediatr Surg. 2012;17:153–6.CrossRefGoogle Scholar
  8. 8.
    Kaur H, Ghosh A, Rudramurthy SM, Chakrabarti A. Gastrointestinal mucormycosis in apparently immunocompetent hosts—a review. Mycoses. 2018;61(12):898–908.CrossRefGoogle Scholar
  9. 9.
    Castagnola E, Buratti S. Clinical aspects of invasive candidiasis in paediatric patients. Drugs. 2009;69(Suppl 1):45–50.CrossRefGoogle Scholar
  10. 10.
    Manzoni P, Mostert M, Galletto P, et al. Is thrombocytopenia suggestive of organism-specific response in neonatal sepsis? Pediatr Int. 2009;51:206–10.CrossRefGoogle Scholar
  11. 11.
    Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):409–17.CrossRefGoogle Scholar
  12. 12.
    Kaufman DA. Challenging issues in neonatal candidiasis. Curr Med Res Opin. 2010;26:1769–78.CrossRefGoogle Scholar
  13. 13.
    Ericson JE, Kaufman DA, Kicklighter SD, Bhatia J, Testoni D, Gao J, et al. Fluconazole Prophylaxis Study Team on behalf of the Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee; Fluconazole Prophylaxis Study Team on behalf of the Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. Fluconazole prophylaxis for the prevention of candidiasis in premature infants: a meta-analysis using patient-level data. Clin Infect Dis. 2016;63:604–10.Google Scholar
  14. 14.
    Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics. 1999;103(4):e39.CrossRefGoogle Scholar
  15. 15.
    Zaoutis TE, Prasad PA, Localio AR, Coffin SE, Bell LM, Walsh TJ, Gross R. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis. 2010;51:e38–45.CrossRefGoogle Scholar
  16. 16.
    Singhi S, Rao DS, Chakrabarti A. Candida colonization and candidemia in a pediatric intensive care unit. Pediatr Crit Care Med. 2008;9:91–5.CrossRefGoogle Scholar
  17. 17.
    Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015;41:285–95.CrossRefGoogle Scholar
  18. 18.
    Calitri C, Caviglia I, Cangemi G, Furfaro E, Bandettini R, Fioredda F, et al. Performance of 1,3-β-D-glucan for diagnosing invasive fungal diseases in children. Mycoses. 2017;60:789–95.CrossRefGoogle Scholar
  19. 19.
    Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care. 2011;1(1):37.CrossRefGoogle Scholar
  20. 20.
    Kumar S, Bansal A, Chakrabarti A, Singhi S. Evaluation of efficacy of probiotics in prevention of candida colonization in a PICU—a randomized controlled trial. Crit Care Med. 2013;41:565–72.CrossRefGoogle Scholar
  21. 21.
    Romanio MR, Coraine LA, Maielo VP, Abramczyc ML, Souza RL, Oliveira NF. Saccharomyces cerevisiae fungemia in a pediatric patient after treatment with probiotics. Rev Paul Pediatr. 2017;35(3):361–4.CrossRefGoogle Scholar
  22. 22.
    Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:e327–40.CrossRefGoogle Scholar
  23. 23.
    Kumar J, Singh A, Seth R, Xess I, Jana M, Kabra SK. Prevalence and predictors of invasive fungal infections in children with persistent febrile neutropenia treated for acute leukemia—a prospective study. Indian J Pediatr. 2018;85:1090–5. Scholar
  24. 24.
    Lin GL, Chang HH, Lu CY, Chen CM, Lu MY, Lee PI, et al. Clinical characteristics and outcome of invasive fungal infections in pediatric acute myeloid leukemia patients in a medical center in Taiwan. J Microbiol Immunol Infect. 2018;51:251–9.CrossRefGoogle Scholar
  25. 25.
    De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.Google Scholar
  26. 26.
    Dvorak CC, Fisher BT, Sung L, Steinbach WJ, Nieder M, Alexander S, Zaoutis TE. Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data. Pediatr Blood Cancer. 2012;59:21–6.CrossRefGoogle Scholar
  27. 27.
    Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.CrossRefGoogle Scholar
  28. 28.
    Mandhaniya S, Swaroop C, Thulkar S, Vishnubhatla S, Kabra SK, Xess I, Bakhshi S. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study. J Pediatr Hematol Oncol. 2011;33:e333–41.CrossRefGoogle Scholar
  29. 29.
    Antachopoulos C. Invasive fungal infections in congenital immunodeficiencies. Clin Microbiol Infect. 2010;16:1335–42.CrossRefGoogle Scholar
  30. 30.
    Siberry GK, Abzug MJ, Nachman S. Panel on Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Executive summary: 2013 update of the guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Pediatr Infect Dis J. 2013;32:1303–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Kokilaben Dhirubhai Ambani Hospital and Medical Research InstituteMumbaiIndia
  2. 2.Department of PaediatricsKokilaben HospitalMumbaiIndia

Personalised recommendations